Search the Newsreel

IDEX shares jump nearly 4% on Q2 beat and raise

IDEX Corporation (NYSE:IEX) reported better-than-expected Q2 results and raised its full-year guidance, leading to a nearly 4% jump in premarket shares. The company posted adjusted EPS of $2.32 and revenue of $921 million, exceeding analyst estimates. Strong organic sales growth was seen in the …

IDEX Corp (IEX) Q2 Earnings: EPS Hits $1.93, Revenue at $921 Mil

IDEX Corp (IEX) reported strong Q2 2026 earnings with record sales of $921 million, an 11% increase in diluted EPS to $1.93, and orders exceeding $1 billion. Despite strong performance in Health & Science Technologies, the Fire & Safety/Diversified Products segment saw a slight …

Earnings Flash (IEX) IDEX Corporation Reports Q2 Revenue $920.6M, vs. FactSet Est of $905.4M

IDEX Corporation reported its Q2 revenue at $920.6 million, surpassing FactSet's estimate of $905.4 million. The company also provided forward-looking guidance, expecting Q3 adjusted EPS in the range of $2.20 - $2.25 and full-year 2026 adjusted EPS between $8.70 and $8.85, both exceeding analyst …

Earnings Flash (IEX) IDEX Corporation Posts Q2 Adjusted EPS $2.32 per Share, vs. FactSet Est of $2.11

IDEX Corporation reported its Q2 adjusted EPS at $2.32 per share, exceeding FactSet's estimate of $2.11. This positive earnings surprise highlights the company's strong financial performance during the quarter.

IDEX earnings beat by $0.21, revenue topped estimates

IDEX reported strong second-quarter results, beating analyst estimates with an EPS of $2.32 against a predicted $2.11, and revenue reaching $921 million, surpassing the $905.37 million consensus. The company also issued optimistic guidance for Q3 and the full fiscal year 2026, indicating continued growth …

Idex: Q2 Earnings Snapshot

IDEX Corp. (IEX) reported second-quarter net income of $143.4 million, translating to $1.93 per share, with adjusted earnings of $2.32 per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $920.6 million. IDEX provided optimistic guidance for the current quarter and …

IDEX Reports Second Quarter Results

Highlights (All comparisons are against the prior year period unless otherwise noted) Record sales of $921 million increased 6% on a reported basis and 5% organically Reported diluted EPS of $1.93 increased 11% and record adjusted diluted EPS of $2.32 increased 12% Record orders …

IDEXX Laboratories (IDXX) Could Be 20% Below Fair Value On Its Diagnostics Growth Story

IDEXX Laboratories Inc (IDXX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for IDEXX Laboratories Inc (IDXX), detailing its volatility, financial risk, and investment risk. The company has a current risk assessment score of 7.69, ranking 31st in the Healthcare Equipment & Supplies industry, and a beta value of 1.56, …

IDEX (IEX) To Report Earnings Tomorrow: Here Is What To Expect

IDEX (IEX) To Report Earnings Tomorrow: Here Is What To Expect Manufacturing company IDEX (NYSE:IEX) will be reporting results this Wednesday before market hours. Here's what investors should know. IDEX beat analysts' revenue expectations last quarter, reporting revenues of $886.9 million, up 8.9% year …

IDEX earnings ahead: Can industrial firm sustain Q1 momentum?

IDEX Corporation is preparing to release its second-quarter results, with analysts anticipating earnings of $2.11 per share on revenues of $905.37 million. Investors will be observing whether the company can maintain momentum in its Health & Science Technologies segment, uphold its strong profit margins, …

IRIX|IRIDEX Corp|Price:0.862|Chg%:-0.019

This article provides a comprehensive stock analysis of IRIDEX Corp (IRIX) by TradingKey, assigning it a score of 6.30/10. Key insights highlight healthy fundamentals, significant growth potential, a fairly valued stock with high institutional ownership, and a "Buy" rating from one analyst with a …

10,800 Shares in IDEX Corporation $IEX Acquired by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. recently acquired 10,800 shares of IDEX Corporation (NYSE:IEX) during the first quarter, valued at approximately $2.047 million. Other institutional investors have also adjusted their holdings in IDEX, with several increasing their stakes. IDEX reported strong quarterly earnings, surpassing analyst …

IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals

IDEXX Laboratories, Inc. has released its 2025 Corporate Responsibility Report, detailing significant progress in innovation, employee support, and environmental stewardship. The report highlights advancements in veterinary diagnostics, substantial investments in workforce development, and reductions in the company's environmental footprint through renewable energy and fleet …

IDEX Gears Up to Report Q2 Earnings: What's in the Cards?

IDEX Corporation (IEX) is preparing to release its Q2 2026 earnings, with analysts expecting revenue growth of 4.3% and a 1.5% increase in adjusted earnings per share. The Health & Science Technologies and Fluid & Metering Technologies segments are projected to show strength due …

Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings

IDEXX Laboratories (IDXX) is set to announce its Q2 2026 earnings on August 4th, with analysts anticipating revenue growth of 8.3% and EPS growth of 8.8%. The company has consistently beaten earnings estimates in the past four quarters. Key drivers for Q2 performance are …

IRIDEX Corp (IRIX) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for IRIDEX Corp (IRIX), covering operating, investing, and financing activities. It presents financial data including operating cash flows, net income, capital expenditures, and free cash flow over several fiscal quarters and years. The …

IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention

Jensen Investment Management's Q2 2026 investor letter highlighted IDEXX Laboratories (IDXX) as a newly added position, citing its durable competitive advantages including high customer retention and recurring revenue from veterinary diagnostic tests. Despite recent weak share-price performance due to a rotation towards cyclical technology, …

IEX|IDEX Corp|Price:223.685|Chg%:+0.415

TradingKey provides a comprehensive stock analysis of IDEX Corp (IEX), noting its healthy fundamentals, high growth potential, and fair valuation within its industry. The company is a high dividend payer, but has seen institutional selling recently. Analysts largely rate the stock as "Buy" with …

IDEXX Laboratories stock holds firm on recurring diagnostics demand

IDEXX Laboratories reported strong fiscal 2025 results, with revenue reaching $3.9 billion and an operating margin of 31.0%. The company's profitability and growth are driven by recurring veterinary diagnostics demand, especially a 14% increase in companion animal diagnostic recurring revenue. This consistency in expanding …

Arrowstreet Capital Limited Partnership Boosts Holdings in IDEX Corporation $IEX

Arrowstreet Capital Limited Partnership increased its stake in IDEX Corporation by 51.1% in the first quarter, now owning 699,788 shares valued at $132.6 million. This comes as IDEX reported strong quarterly earnings, surpassing analyst expectations with $2.00 EPS and $886.9 million in revenue. Analysts …

IDEX (IEX) Stock Trades At A Discount On Cash Flow But A Premium On Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. IDEX has risen 24.7% year to date, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow …

IRIDEX Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed overview of IRIDEX Corp (IRIX), an ophthalmic medical technology company specializing in laser-based systems for treating glaucoma and retina disorders. It includes company background, executive information, key financial data such as market cap and P/E, and a breakdown of …

IRIDEX Corp (IRIX) Income Statement

This article provides IRIDEX Corp's (IRIX) quarterly and annual income statements, detailing financial performance metrics such as total revenue, cost of revenue, operating expenses, and net income. It allows users to gain insights into the company's operational efficiency and trends across various fiscal periods. …

IDEX Corp (IEX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of IDEX Corp (IEX), listing its major institutional holders and their respective proportions. It also presents institutional shareholding trends over several quarters and highlights related ETFs that include IEX in their portfolios. The data provides insight into the …

IRIDEX Corp (IRIX) Earnings Date & Reports & Earnings News

IRIDEX Corp (IRIX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of IRIDEX Corp (IRIX)'s financial health, noting its current score of 7.17 and ranking within the Healthcare Equipment & Supplies industry. It highlights a stable financial status with average operating efficiency despite recent decreases in quarterly revenue and net …

IRIDEX Corp (IRIX) Institutional Confidence

The article provides an overview of IRIDEX Corp's institutional confidence score, which is currently 3.00, placing it 131st in the Healthcare Equipment & Supplies industry. Institutional shareholding has increased to 21.29%, a 16.49% rise quarter-over-quarter. The largest institutional shareholder is James Simons, and the …

Gabelli Funds LLC Decreases Stock Holdings in IDEX Corporation $IEX

Gabelli Funds LLC reduced its stake in IDEX Corporation (NYSE:IEX) by 2.8% in the first quarter, now owning 176,100 shares valued at $33.38 million. Other institutional investors adjusted their holdings as well, with total institutional ownership for IEX standing at 97.96%. The article also …

IDEX Corporation Revenue Breakdown – MIL:1IEX

IDEX Corporation's top-performing segment last year was Health & Science Technologies, generating EUR 1.27 billion. The United States was the largest contributor to the company's revenue, accounting for EUR 1.50 billion. The company's total revenue for the last year was EUR 2.94 billion.

IRIDEX Corp (IRIX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of IRIDEX Corp's (IRIX) dividend and stock split history. It indicates that the company has distributed a total of $0.00 in dividends over the past five years and that there is no dividend data available. The content primarily focuses …

IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for IDEXX Laboratories Inc (IDXX), highlighting its current earnings forecast score of 7.75 and an average analyst price target of USD 787.50. It details analyst ratings, peer comparisons, and frequently asked questions regarding revenue, EPS, and overall stock …

IDEXX Laboratories Inc (IDXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of IDEXX Laboratories Inc (IDXX) revenue by business segments and geographical regions. It highlights that CAG Diagnostics recurring revenue is the largest contributor, making up 79.17% of total revenue, with the United States accounting for the majority of …

IDEXX Laboratories Inc (IDXX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of IDEXX Laboratories Inc's (IDXX) dividends and stock splits, although it notes that no dividend data is available. It reports the current stock price, market cap, and P/E ratio for IDEXX, indicating that the company has not distributed dividends …

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Despite a recent 9% drop in share price over three months, IDEXX Laboratories (NASDAQ:IDXX) exhibits strong financials, including a high Return on Equity (ROE) of 55%. The company's strategy of reinvesting all profits, coupled with this high ROE, has led to a 15% net …

IDXX|IDEXX Laboratories Inc|Price:539.590|Chg%:-5.410

IDEXX Laboratories Inc (IDXX) shows strong fundamentals with high growth potential, though its valuation is considered fair within its industry. Institutional ownership is high, and analysts currently rate the stock as "Buy" with a target price reflecting significant upside. The stock is currently trading …